vs
BioRestorative Therapies, Inc.（BRTX）与Charming Medical Ltd（MCTA）财务数据对比。点击上方公司名可切换其他公司
BioRestorative Therapies, Inc.是一家临床阶段生物技术企业，专注于创新再生医学疗法的研发，核心管线覆盖慢性腰痛、代谢类疾病等未被满足的医疗需求领域，主要面向北美市场，推进细胞类创新候选治疗产品的临床开发工作。
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收
BRTX
MCTA
| Q4 25 | $19.6K | — | ||
| Q3 25 | $11.8K | — | ||
| Q2 25 | $303.3K | — | ||
| Q1 25 | $25.0K | — | ||
| Q4 24 | $43.3K | — | ||
| Q3 24 | $233.6K | — | ||
| Q2 24 | $89.1K | — | ||
| Q1 24 | $35.0K | — |
净利润BRTXMCTA
| Q4 25 | $-3.2M | — | ||
| Q3 25 | $-3.0M | — | ||
| Q2 25 | $-2.7M | — | ||
| Q1 25 | $-5.3M | — | ||
| Q4 24 | $-1.6M | — | ||
| Q3 24 | $-1.1M | — | ||
| Q2 24 | $-4.0M | — | ||
| Q1 24 | $-2.2M | — |
毛利率BRTXMCTA
| Q4 25 | 91.7% | — | ||
| Q3 25 | 10.4% | — | ||
| Q2 25 | 97.1% | — | ||
| Q1 25 | 88.4% | — | ||
| Q4 24 | 92.3% | — | ||
| Q3 24 | 92.2% | — | ||
| Q2 24 | 92.7% | — | ||
| Q1 24 | 100.0% | — |
营业利润率BRTXMCTA
| Q4 25 | -19516.8% | — | ||
| Q3 25 | -31432.3% | — | ||
| Q2 25 | -1089.8% | — | ||
| Q1 25 | -19230.1% | — | ||
| Q4 24 | -6212.8% | — | ||
| Q3 24 | -979.0% | — | ||
| Q2 24 | -2770.8% | — | ||
| Q1 24 | -11740.7% | — |
净利率BRTXMCTA
| Q4 25 | -16365.5% | — | ||
| Q3 25 | -25748.1% | — | ||
| Q2 25 | -875.8% | — | ||
| Q1 25 | -21359.2% | — | ||
| Q4 24 | -3778.6% | — | ||
| Q3 24 | -467.2% | — | ||
| Q2 24 | -4521.4% | — | ||
| Q1 24 | -6352.2% | — |
每股收益（稀释后）BRTXMCTA
| Q4 25 | $-0.31 | — | ||
| Q3 25 | $-0.33 | — | ||
| Q2 25 | $-0.30 | — | ||
| Q1 25 | $-0.64 | — | ||
| Q4 24 | $-0.20 | — | ||
| Q3 24 | $-0.13 | — | ||
| Q2 24 | $-0.50 | — | ||
| Q1 24 | $-0.33 | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
